Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
The Maire - EuroChem Case: Three Lessons for Global Business 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
 - EconoTimes)
Active Biotech's Annual Report 2016 is now available för download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English version will be available within short.
Lund, May 18, 2017
Tomas Leanderson
President & CEO
For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 14.30 am CET on May 18, 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ed0692b0-c7c4-4c9a-9f8a-e924a3ed2a54
